Paul Tudor Jones Editas Medicine, Inc. Transaction History

Tudor Investment Corp Et Al

$15.5 Billion
Q1 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 31,321 shares of EDIT stock, worth $146,269. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,321

Holding current value

$146,269

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $220,186 - $346,723	31,321 New	31,321 $232,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $141,615 - $226,165	11,646 New	11,646 $143,000
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $226,693 - $484,474	-22,692 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $218,958 - $429,674	-15,551 Reduced 40.66%	22,692 $432,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $720,062 - $1.1 Million	27,121 Added 243.85%	38,243 $1.02 Million

Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $437,624 - $812,843	-11,144 Reduced 50.05%	11,122 $457,000
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $696,703 - $1.26 Million	22,266 New	22,266 $1.26 Million
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $3.59 Million - $4.76 Million	-128,111 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $1.63 Million - $3.02 Million	87,927 Added 218.81%	128,111 $3.79 Million
Q1 2020 May 15, 2020	BUY	$14.88 - $32.78 $250,445 - $551,720	16,831 Added 72.07%	40,184 $797,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $455,149 - $762,008	23,353 New	23,353 $691,000
Q4 2017 Feb 14, 2018	SELL	$21.89 - $31.34 $895,410 - $1.28 Million	-40,905 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $646,708 - $982,129	40,905	40,905 $982,000

Others Institutions Holding EDIT

# of Institutions

243

Shares Held

69.3M

Call Options Held

564K

Put Options Held

428K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $321M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account